Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AIC 100

Next Previous
Drug Profile

AIC 100

Alternative Names: AIC-100

Latest Information Update: 30 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AffyImmune Therapeutics; National Cancer Institute (USA)
  • Developer AffyImmune Therapeutics; Weill Cornell Medicine
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I Thyroid cancer
  • Preclinical Cervical cancer; Gastric cancer; Non-small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 23 Sep 2024 AffyImmune Therapeutics plans a phase I trial for Non-small cell lung cancer
  • 23 Sep 2024 AffyImmune Therapeutics plans a phase II trial for Thyroid cancer (Late-stage disease)
  • 23 Jul 2024 AIC 100 receives Regenerative Medicine Advanced Therapy (RMAT) status for Thyroid cancer (Late-stage disease, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top